Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>CLSA Keeps Rating at Outperform for JD HEALTH (06618.HK), Raises Earnings Forecasts
Recommend 7 Positive 6 Negative 3 |
||||
|
||||
|
CLSA released a research report expecting that JD HEALTH (06618.HK) will maintain its growth momentum in 2H25, driven by decent sales performance during Double 11 and a surge in flu inflections in December, with revenue increasing by 24.5% YoY to RMB37.1 billion. The broker continued to estimated that, supported by gross margin expansion and operational leverage, adjusted EBIT may double YoY to RMB2.1 billion, and the Company's 2026 revenue will grow by 16% YoY. CLSA raised its FY2026/ 2027 adjusted net profit forecasts for JD HEALTH by 1%/ 2% each to reflect the recovery in drug sales and profit expansion prospects. Therefore, the broker reiterated rating at Outperform, and kept its target price at $71. AAStocks Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
